Form 4: Akari Therapeutics Director Abizer Gaslightwala Acquires Shares

Director Abizer Gaslightwala of Akari Therapeutics Plc acquired 11,439 American Depository Shares at $1.22 each on January 10, 2025.

Summary

• Abizer Gaslightwala, a director at Akari Therapeutics Plc, acquired 11,439 American Depository Shares (ADS) on January 10, 2025.
• The purchase price was $1.22 per ADS.
• Each ADS represents 2,000 ordinary shares of Akari Therapeutics.
• Following the transaction, Mr. Gaslightwala's holdings include 35,860 ADS.

Sentiment

Score: 6

Explanation: The document is a routine filing of a director's share purchase. It is neither particularly positive nor negative, but a director buying shares is generally seen as a positive sign.

Positives

• A director's purchase of shares can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for all publicly traded companies in the United States.
• The transaction is typical for directors and officers who are required to disclose their trades in company stock.
• The size of the transaction is not unusual for a director's purchase.

Stakeholder Impact

• The share purchase may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Akari Therapeutics, Director Share Purchase, Abizer Gaslightwala, ADS, Share Acquisition, Insider Trading